TSX News -
IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress
73% of tumor regressions and 80% of clinical responses were observed in a subpopulation defined by a clinical biomarker based […]